분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-02-01 15:40:10 , Hit : 672
 Shields Up for New Cancer Gene-Therapy Virus


GEN News Highlights
More »
January 31, 2018

https://www.genengnews.com/gen-news-highlights/shields-up-for-new-cancer-gene-therapy-virus/81255442/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20180131

The promise of gene therapy to treat cancer has always been limited by the vector used to deliver the rectified genetic payload. While off-targeting has always been a major concern, no less of an issue is the host immune system destroying the therapeutic virus before it has had a chance to complete its mission. Now, investigators at the University of Zurich (UZH) have developed a vector they believe will dramatically increase the efficiency of cancer gene therapy using human adenovirus 5. The findings from the new study were released today in Nature Communications, in an article entitled “Adenoviral Vector with Shield and Adapter Increases Tumor Specificity and Escapes Liver and Immune Control.”

There are innumerable different viruses that can be utilized for gene therapy efforts, but the human adenovirus 5, which normally causes the symptoms of a typical cold, has one substantial advantage: Its genome can be replaced completely by an artificial one that contains only "useful" genes. Without any of the viral genes left, the virus can no longer replicate and trigger diseases. In addition, the genome of the adenovirus is very large and does not integrate into human chromosomes.

Until recently, the use of adenoviruses in tumor therapy has been very limited. They lack the ability to infect cancer cells and therefore cannot inject the genetic blueprints for the therapeutic molecules to fight the disease. Moreover, adenoviruses are efficiently neutralized by the immune system and very rapidly eliminated by the liver. This new study shows how researchers succeeded in rebuilding these viruses so that they effectively recognize and infect tumor cells. "For this purpose, we have created molecules that act as an adapter between the virus and the tumor cell," explained lead study investigator Markus Schmid, Ph.D., professor in the department of biochemistry at the University of Zurich.

The adapters, which cling very tightly to the coat of the virus, can—depending on their version—bind to different surface molecules on the tumor cell. The scientists tested adapters for several receptors such as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), which are present on several types of cancer cells. Only viruses equipped with these adapters could infect the tumor cells.

“[We engineered] a high-affinity protein coat, shielding the most commonly used vector in clinical gene therapy, human adenovirus type 5,” the authors wrote. “Using electron microscopy and crystallography we demonstrate a massive coverage of the virion surface through the hexon-shielding scFv fragment, trimerized to exploit the hexon symmetry and gain avidity. The shield reduces virion clearance in the liver. When the shielded particles are equipped with adaptor proteins, the virions deliver their payload genes into human cancer cells expressing HER2 or EGFR.”

The researchers subsequently hid the virus under a novel protein coat, which serves as camouflage for the virus and which protects it from the immune system. As a basis for this shield, the researchers used an existing antibody that they redesigned.

“When the shielded particles are equipped with adaptor proteins, the virions deliver their payload genes into human cancer cells expressing HER2 or EGFR,” the authors explained. “The combination of shield and adapter also increases viral gene delivery to xenografted tumors in vivo, reduces liver off-targeting and immune neutralization. Our study highlights the power of protein engineering for viral vectors overcoming the challenges of local and systemic viral gene therapies.”

Interestingly, the shield not only protects the redesigned virus from the immune cells but also prevents the virus from being eliminated by the liver, which normally quickly removes unmodified adenoviruses from the bloodstream, often making therapeutic applications impossible. With its shield and its adapter, these viral gene shuttles efficiently infected tumor cells in laboratory animals.

Using these stealth gene shuttles, the UZH scientists want to develop novel therapies for several types of cancer. The numerous advantages of adenoviruses will likely help to tackle one of the greatest problems of cancer medicine—the development of resistance against drugs.

"With this gene shuttle, we have opened up many avenues to treat aggressive cancers in the future, since we can make the body itself produce a whole cocktail of therapeutics directly in the tumor,” concluded senior study investigator Andreas Plückthun, Ph.D., director in the department of biochemistry at the University of Zurich.







27   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 690
26   Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 690
25   Scientists Doubt Results of CRISPR’d Embryos  이성욱 2017/09/02 681
24   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 674
  Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 672
22   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 668
21   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 664
20   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 654
19   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 653
18   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 652
17   CRISPR/Cas9 Edits Epigenome with Therapeutic Efficiency  이성욱 2017/12/09 637
16   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 625
15   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 614
14   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 592
13   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 550
12   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 535
11   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 533
10   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 525
9   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 520
8   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 518

[이전 10개] [1]..[61][62] 63 [64]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN